Pranav K. Gandhi

Hematology

6501 Coyle Ave
Carmichael, CA 95608

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

The MuFusE large-volume diamond anvil cell for exploring muon-catalyzed fusion at higher pressures and temperatures.

The MuFusE large-volume diamond anvil cell for exploring muon-catalyzed fusion at higher pressures and temperatures.

Journal: The Review of scientific instruments

Published: April 06, 2026

Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial.

Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial.

Journal: The Lancet. Neurology

Published: March 10, 2026

Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparison.

Comparative effectiveness of atogepant and rimegepant for migraine prevention in Japanese patients: an anchored matching-adjusted indirect comparison.

Journal: Expert review of neurotherapeutics

Published: December 18, 2025

Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

Journal: Pain management

Published: November 19, 2025

Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.

Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine.

Journal: Cephalalgia : an international journal of headache

Published: August 20, 2025

Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing.

Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing.

Journal: Headache

Published: January 21, 2025

Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.

Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.

Journal: Neurology

Published: December 23, 2024

Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials.

Effect of preventive treatment with atogepant on quality of life, daily functioning, and headache impact across the spectrum of migraine: Findings from three double-blind, randomized, phase 3 trials.

Journal: Cephalalgia : an international journal of headache

Published: December 09, 2024

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete-choice experiment.

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete-choice experiment.

Journal: Headache

Published: November 27, 2024

Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies.

Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies.

Journal: Cephalalgia : an international journal of headache

Published: November 19, 2024

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial.

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial.

Journal: Neurology

Published: August 28, 2024

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial.

Journal: Neurology

Published: June 26, 2024

Showing 1-12 of 48

Last Updated: 09/26/2026